BioNTech SE Drug Pipeline

BioNTech SE maintains a substantial clinical development portfolio, with 31 active trials out of 70 total trials registered since 2008. The pipeline spans early- to late-stage development, with 14 active Phase 1 trials, 18 in Phase 2, and 10 in Phase 3. The company’s therapeutic focus is heavily weighted toward oncology, which accounts for 23 active trials, or 74% of the active portfolio. Infectious disease programs make up the balance, with 6 active trials. Within oncology, the greatest concentration of activity is in solid tumors (advanced), with 6 active trials including one in Phase 3. Non-small cell lung cancer (NSCLC) is another key indication, with 4 active trials and one in Phase 3. Lung cancer (general) also features prominently, with 3 active trials, one of which is in Phase 3. Breast and colorectal cancers are being investigated in 2 active trials each. The late-stage weighting in oncology suggests potential near-term catalysts for BioNTech.